humanize

(redirected from humanised)
Also found in: Dictionary, Thesaurus.
Related to humanised: Humanised antibody

humanize

(hyo͞o′mə-nīz′)
tr.v. human·ized, human·izing, human·izes
a. To modify (a nonhuman compound, cell, organ, or organism) such that some of its components are replaced with human forms of those components, usually by means of genetic engineering.
b. To replace most of the variable region of (a monoclonal antibody from a nonhuman source) with a human sequence of amino acids so that the resulting antibody is more compatible with the human immune system.

hu′man·i·za′tion (-mə-nĭ-zā′shən) n.
hu′man·iz′er n.

humanized

(hū′mă-nīzd″)
Chemically altered to resemble natural human amino acid sequences. It applies to proteins or polypeptides derived from animals, e.g., mice, that are altered to reduce their antigenic potential.
humanize
References in periodicals archive ?
Chaturvedula Tripura, a cell biologist at the CSIR-Centre for Cellular and Molecular Biology in Hyderabad said the DCMS study has demonstrated "an efficient and promising technology" for addressing ALF through bio-engineering and transplantation of humanised livers.
As part of the accord, Fusion Antibodies first humanised the parental antibody prior to developing the cell line, as well as has achieved a record PCD (picograms per cell per day) of 33.5 in non-fed shake flask cultures which will be able to produce multiple grams per litre in a bioreactor system.
The cell line will now be advanced to cGMP production, whereas the humanised antibody will be evaluated for diagnosis and therapy of invasive pulmonary aspergillosis in humans, Chris Thornton of Isca Diagnostics noted.
8 August 2013 - US Regeneron Pharmaceuticals (NASDAQ:REGN) said Wednesday it had received a US patent covering methods for genetically modifying a mouse to make human antibodies, a technology used in its VelocImmune humanised mice.
The first ChemomAb's monoclonal antibody to be humanised under the collaboration will be CM-101.
The humanised DM-204 mAb showed an improved binding affinity of up to two orders of magnitude compared to the recently announced first-generation parental mouse antibody.
APX003 is a humanised monoclonal antibody directed against VEGF, and is intended for the treatment of multiple malignancies.
Humanised antibody products provider PDL BioPharma Inc (Nasdaq:PDLI) said on Monday that it has entered into a non-exclusive license agreement under its Queen et al patents, with respect to teplizumab as well as other potential next generation anti-CD3 molecules.
Teplizumab, a humanised anti-CD3 monoclonal antibody, is currently being studied by Lilly and its partner MacroGenics for the treatment of individuals with newly-diagnosed type 1 diabetes mellitus.